Table 2.
Adjusteda composite symptom scores according to 25(OH)D clinical cut-off categories (≥75 nmol/L as referentb)
| Menopause-related symptom | 25(OH)D level <25 nmol/Lb | 25(OH)D level ≥25 to <50 nmol/L | 25(OH)D level ≥50 to <75 nmol/L | 25(OH)D level ≥75 nmol/L | P value |
|---|---|---|---|---|---|
| Symptom Totalc | 0.84 (-1.02, 2.70) | 0.85 (-0.7, 2.39) | 0.32 (-1.27, 1.91) | Ref | 0.06 |
| Sleep disturbance constructd | 0.23 (-2.35, 2.80) | 1.04 (-1.10, 3.18) | 0.14 (-2.06, 2.34) | Ref | 0.25 |
| Emotional well beinge | -5.11 (-9.78, -0.45) | -2.87 (-6.18, 0.44) | -1.10 (-4.50, 2.31) | Ref | 0.11 |
| Energy/fatiguee | -1.29 (-11.96, 9.38) | -3.32 (-12.19, 5.54) | 1.33 (-7.78, 10.44) | Ref | 0.39 |
a
Results are adjusted for age, years since menopause, ethnicity, education, BMI category, smoking status, UV exposure, HT use at screening, trial arm (HT or DM), calcium (dietary and supplement), and vitamin D (dietary and supplement).
b
Adjusted coefficients from linear models (with 95 % CI) for difference between symptom scores in each vitamin D category relative to highest vitamin D level ≥75 nmol/L
c
Higher total symptom score indicates more symptoms
d
Higher sleep score indicates greater sleep disturbance
e
Higher score indicates better health